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Although antibodies against the third variable loop (V3) of
the HIV-1 viral envelope glycoprotein are among the ﬁrst
neutralizing antibodies to be detected in infected individuals,
they are normally restricted in their speciﬁcity. X-ray
crystallographic studies of V3-speciﬁc antibodies have con-
tributed to a more thorough understanding of recognition of
this epitope and of conserved features in the V3 loop that
could potentially aid in the design of a multi-component
vaccine. The human antibody 447-52D exhibits relatively
broad neutralization of primary viral isolates compared with
other V3-loop antibodies. A crystal structure of Fab 447-52D
in complex with a V3 peptide (UG1033) was determined at
2.1 A ˚ resolution. The structure was determined using an
epitaxially twinned data set and in-house programs to detect
and remove overlapping reﬂections. Although the processed
data have lower than desired completeness and slightly higher
than normal R values for the resolution, good-quality
electron-density maps were obtained that enabled structure
determination. The structure revealed an extended CDR H3
loop that forms a  -sheet with the peptide, with the
predominant contacts being main-chain hydrogen bonds.
The V3 peptide and Fab show high structural homology with
the previously reported structures of other Fab 447-52D
complexes, reinforcing the idea that the V3 loop may adopt a
small set of conserved structures, particularly around the
crown of the  -hairpin.
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1. Introduction
The human immunodeﬁciency virus type 1 (HIV-1) envelope
is a highly glycosylated trimer of heterodimers, composed of
gp120, which mediates binding to the cell-surface CD4
receptor and chemokine co-receptors, and gp41, a trans-
membrane protein that is involved in membrane fusion.
Despite its exposure on the viral surface, the HIV-1 envelope
spike, which is the target of neutralizing antibodies, has
evolved many diverse mechanisms to escape the humoral
immune response. Extensive glycosylation of the exposed
envelope protein, which gives rise to an immunologically silent
‘glycan shield’, and exposure of regions of gp120 that are
highly variable in sequence, termed the V1–V5 hypervariable
loops, are among the major mechanisms that contribute to the
ability of HIV-1 to evade the antibody response during
infection (Burton et al., 2005; Pantophlet & Burton, 2006; Wei
et al., 2003; Wyatt et al., 1998). The glycan shield results in a
general dampening of the immune response, whereas the
immunodominant variable loops tend to elicit neutralizing
antibodies that exhibit strain-speciﬁc neutralization.The third hypervariable (V3) loop of gp120 was initially
known as the principal neutralizing determinant of HIV-1
owing to its ability to readily elicit anti-HIV-1 antibodies (Gao
et al., 2005; Goudsmit et al., 1988; Javaherian et al., 1989, 1990;
Rusche et al., 1988). The anti-V3 antibodies induced early in
infection and after limited exposure to immunogens are
relatively type-speciﬁc; however, anti-V3 antibodies that
display broader reactivity have been reported (Binley et al.,
2004; Gorny et al., 2002, 2006; Krachmarov et al., 2005;
Pantophlet et al., 2007; Richman et al., 2003). The neutraliza-
tion activity of anti-V3 antibodies may be affected by the
propensity of the V3 region to undergo sequence changes that
alter neutralizing-antibody epitopes and give rise to escape
mutants during the course of infection (Hartley et al., 2005;
Richman et al., 2003), epitope masking by the V1/V2 domain
(Hartley et al., 2005; Pantophlet & Burton, 2006; Pinter et al.,
2004) and/or the presence of glycans (Back et al., 1994; Koch et
al., 2003; McCaffrey et al., 2004).
However, human V3-speciﬁc monoclonal antibodies
(mAbs) have been described that exhibit neutralization of
multiple primary HIV-1 isolates, suggesting that this region
may indeed be a worthwhile target in a multi-component
HIV-1 vaccine. The antibody 447-52D, which was originally
isolated from an HIV-1-infected individual (Gorny et al., 1992,
1993), is one of several anti-V3 monoclonal antibodies (Gorny
et al., 2004, 2006) that exhibit signiﬁcant neutralizing breadth
(Binley et al., 2004). Immunochemical studies mapped the core
epitope to a GPxR motif in the crown of the V3 loop (Keller et
al., 1993). Although this motif is prevalent within subtype B
isolates, the dominant crown motif of non-clade-B isolates
is GPGQ (http://www.hiv.lanl.gov/content/hiv-db). In one
analysis, Fab 447-52D neutralized 50% of 32 clade-B viruses
(Binley et al., 2004); in a second study, 92% of 38 primary
isolates containing the GPGR crown motif could be neutral-
ized (Zolla-Pazner et al., 2004). The V3-speciﬁc mAb 2219,
which was also derived from an HIV-1-infected individual,
similarly exhibits neutralization of a relatively large propor-
tion of HIV-1 isolates (Gorny et al., 2002, 2004). More recently,
human mAb F425-B4e8 has been reported to exhibit cross-
neutralizing activity comparable to those of Fab 447-52D and
Fab 2219 (Pantophlet et al., 2007).
In addition to being a potential target for a neutralizing
epitope in an HIV-1 vaccine, the V3 loop plays an important
role in virus infectivity. The sequence of the V3 loop can
inﬂuence cell tropism (Hoffman & Doms, 1999) and this loop
is thought to interact with the chemokine co-receptors CCR5
or CXCR4 during infection (Basmaciogullari et al., 2002;
Rizzuto & Sodroski, 2000; Rizzuto et al., 1998). The V3 region
is composed of approximately 35 residues and contains a
conserved disulﬁde bridge at the base of the loop. A recent
crystal structure of an HIV-1 gp120 core containing an intact
V3 loop reveals that this region contains three structurally
distinct domains: a conserved base, a crown or tip region
(apex) and a ﬂexible stem that links the base and crown
(Huang et al., 2005). Antibody-binding studies performed in
the presence of soluble CD4 suggest that the V3 loop may
become more accessible upon CD4 binding (Mbah et al.,
2001). Such an extended structure could help to explain the
immunodominance of the V3 loop. Cryo-electron tomography
studies performed with SIV virions suggest two possible
models for the location of the V3 loop within the context of
the trimeric envelope. In the ﬁrst, the V3 loop is solvent-
exposed and positioned away from the trimer interface along
the outer side of gp120 (Zhu et al., 2006). Alternatively, the V3
region may be packed into the trimer interface and become
exposed upon CD4-envelope ligation owing to structural
rearrangement of the trimer (Zanetti et al., 2006).
To gain a better understanding of the conformation of the
V3 loop and of the basis for neutralization by V3 mAbs,
structural studies of anti-V3 mAbs in complex with V3
peptides have been undertaken. To date, X-ray crystallo-
graphic structures of four murine anti-V3 Fabs (50.1, 58.2,
59.1, 83.1) have been determined for the Fabs in complex with
V3 peptides corresponding to the HIV-1 isolate MN (Ghiara et
al., 1994, 1997; Rini et al., 1993; Stanﬁeld et al., 1993, 1999,
2003). The crystal structure of human Fab 447-52D has also
been determined in complex with an MN peptide (Stanﬁeld et
al., 2004) and, more recently, crystal structures of Fab 2219 in
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Table 1
Comparison of the six different data-processing and initial test reﬁnements of the epitaxially twinned data.
Data set no. 1 2 3 4 5 6
Lattice 1 Lattice 2 Lattice 1 + 2 Lattice 1† Lattice 2† Lattice 1 + 2†
No. of spots‡ 2346478 2350364 4696842 1810397 1814960 3625357
No. of overlapping spots deleted by in-house program 0 0 0 536081 535405 1071485
No. of observations§ 206766 215665 427782 153463 159567 310899
No. of observations rejected by SCALEPACK 26884 29981 89699 15236 15350 49923
No. of unique reﬂections} 68033 68897 69984 56663 57482 60586
Completeness (%) 96.9 97.4 98.9 80.6 81.3 85.7
Redundancy 3.0 3.1 6.1 2.7 2.8 5.1
hI/ (I)i 23.6 24.1 34.4 19.5 19.7 27.1
Rmerge 6.7 (32.9) 6.7 (34.5) 8.3 (39.4) 6.8 (38.7) 6.9 (38.8) 8.4 (44.5)
Rrigid†† 38.1 37.6 37.7 36.7 36.6 36.4
Rcryst/Rfree 30.9/34.4 30.4/33.7 30.3/34.2 29.7/33.2 29.4/33.9 29.1/32.9
† The last three columns are with overlaps manually deleted, whereas the ﬁrst three columns are with no manual deletion of overlapping spots. ‡ Spots are deﬁned as the two-
dimensional diffraction peak from a single image frame. In most cases, these are partial reﬂections. § Observations are the integrated intensity formed by the proﬁle-ﬁtted summation
of the partial spots. } Reﬂections are the average of multiply measured and symmetry-related observations. †† Rrigid is the Rcryst value from the initial rigid-body reﬁnement with
resolution limits of 15–4 A ˚ .complex with three different V3 peptides, corresponding to
isolates UG1033, MN and UR29, have been reported (Stan-
ﬁeld, Gorny et al., 2006).
The MN V3 peptide adopts a similar conformation in
complex with the murine Fabs 50.1, 59.1 and 83.1, whereas a
different V3-crown structure is observed in the Fab 58.2
complex. In the former, residues upstream of the crown form
an extended  -sheet, with a type I or II  -turn around the
GPGR crown motif. The V3 peptide in the Fab 58.2 complex
adopts a different conformation at the crown that contains two
consecutive turns. The V3 peptides in the Fab 447-52D and
Fab 2219 crystal structures show structural homology to these
murine Fab complexes, adopting  -hairpin structures,
although the relative orientation of the N- and C-terminal
strands in the Fab 2219 peptides differs owing to a differing
torsion angle of a single residue within the N-terminal strand.
These V3 structures are also comparable to the conformation
observed in the V3-containing core gp120 structures (Huang et
al.,2005, 2007; Stanﬁeld & Wilson, 2005). Finally,NMR studies
of the Fv fragment of 447-52D in complex with V3 peptides
corresponding to isolates MN and IIIb show that the peptides
in both of these complexes form  -hairpin structures and
exhibit the same N-terminal conformation (Rosen et al., 2005;
Sharon et al., 2003).
Here, we report the processing strategy for an epitaxially
twinned data set (Table 1) and the details of the resulting
2.1 A ˚ structure of the UG1033 V3 peptide bound to Fab 447-
52D. We also discuss insights gained from a comparative
analysis of this new structure with those previously reported
for other V3-peptide complexes of Fab 447-52D.
2. Experimental
2.1. Fab production and purification
IgG 447-52D (IgG3,  ) was produced and puriﬁed as
previously reported (Gorny et al., 1989, 1991). Brieﬂy, pooled
peripheral blood cells from two HIV-1-infected patients were
transformed and fused to a human/mouse hetero-myeloma
cell line (SHM-D33). The Mab 447-52D heterohybridoma was
selected based on its ability to bind a peptide corresponding to
a portion of the V3 sequence of the HIV-1 isolate MN (YN-
KRKRIGIGPGRAFYTTKNIIG) and then repeatedly cloned
until monoclonality was achieved. Fab fragments were
prepared by IgG 447-52D cleavage with 4% papain in 10 mM
l-cysteine for 4 h. Fab 447-52D was puriﬁed on Protein A,
Superdex 200 (10/30 column; 0.2 M sodium acetate pH 5.5)
and Mono S columns (10/10 column; buffer A =5 0 m M
sodium acetate pH 4.5; buffer B =5 0m M sodium acetate, 1 M
sodium chloride pH 4.5).
2.2. Crystallization
A 23-mer V3 peptide, UG1033 (NNTRKSIHLGP-
GRAFYATGDIIG), was used for cocrystallization. Fab 447-
52D (20 mg ml
 1) and UG1033 peptide were mixed in a 1:5
molar ratio and crystals were grown using the standard sitting-
drop vapor-diffusion method. Thin intergrown crystal plates
which could not be readily separated were grown from 1.4 M
ammonium sulfate, 0.1 M cacodylate pH 6.5 and did not
diffract beyond 2.5 A ˚ . However, screening of these conditions
with Hampton Additive Screen 1 revealed larger single-crystal
plates with CuCl2 as an additive. Crystals that visually
appeared to be single were grown using a ﬁnal reservoir
solution of 1.58 M ammonium sulfate, 0.1 M Tris pH 7.88,
1m M CuCl2. Crystals were cryopreserved by brief immersion
into a solution consisting of the reservoir solution augmented
with 25% glycerol. Data were collected to 2.1 A ˚ resolution on
SSRL beamline 11-1 with a 0.25  step size and a crystal-to-
detector distance of 250 mm on an ADSC Q315 detector and
reduced in space group P21 with unit-cell parameters a = 70.5,
b = 75.9, c= 114.1 A ˚ ,  = 101.5 . The Matthews coefﬁcient was
3.0 A ˚ 3 Da
 1 (Matthews, 1985), corresponding to 59% solvent
content. Data were indexed, integrated and scaled with HKL-
2000 (Otwinowski & Minor, 1997) to 2.1 A ˚ resolution
(Table 2). Multiple lattices were detected in all crystals that
were screened. Twinned data sets were resolved using
DENZO/SCALEPACK (Otwinowski & Minor, 1997) and in-
house programs, as described below in x3.
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Table 2
Processing and ﬁnal reﬁnement statistics for data set 6.
Values in parentheses are for the last shell.
Data collection
Space group P21
Unit-cell parameters (A ˚ ,  ) a = 70.5, b = 75.9,
c = 114.1,   = 101.5
Resolution (A ˚ ) 50–2.1 (2.15–2.10)
No. of observations 310899 (13751)
No. of unique reﬂections 60586 (3035)
Completeness (%) 85.7 (86.0)
Redundancy 5.1 (4.5)
hI/ (I)i 27.1 (4.0)
Rmerge 8.4 (44.5)
Reﬁnement statistics
Rcryst 24.1 (29.9)
Rfree 29.8 (37.5)
No. of waters 188
R.m.s.d. from ideal geometry
Bond lengths (A ˚ ) 0.017
Angles ( )1 . 6
B values† (A ˚ 2)
Fab 1
VL 29.4
CL 31.1
VH 34.1
CH1 31.3
Peptide 57.8
Fab 2
VL 53.7
CL 52.2
VH 49.8
CH1 39.9
Peptide 82.8
Waters 34.6
Overall 40.8
Ramachandran plot
Most favored (%) 88.5
Additionally allowed (%) 11.0
Generously allowed (%) 0.1
Disallowed (%) 0.4
† B values are the sum of TLS and residual B factors.research papers
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Figure 1
Raw data from the epitaxially twinned data set. The frames are displayed with the XDISPLAYF (Otwinowski & Minor, 1997) software, and the images
have been cropped to show only the strongly diffracting spots. (a) The ﬁrst diffraction image (crystal to detector distance = 250 cm, oscillation angle =
0.25 ). (b) Spots (diffraction maxima) corresponding to the ﬁrst lattice are shown in green, after separation of the spot ﬁle into two ﬁles for the two
different lattices, as described in x3. (c) Spots (green) corresponding to the second lattice. (d) The same image with all spots (green) from both lattices
selected for auto-indexing by XDISPLAYF.2.3. Structural determination and refinement
The structure was determined by molecular replacement
using the reﬁned structure of Fab 447-52D (PDB code 1q1j) as
a search model. Two Fab–peptide complexes were present in
the asymmetric unit and were related by an NCS twofold
around x (or z). Alternating cycles of model building and
positional reﬁnement were carried out using TOM/FRODO
(Jones, 1982) and CNS (Bru ¨nger et al., 1998). Tight NCS
restraints were used early in reﬁnement and then gradually
released. Final rounds of reﬁnement were carried out using
REFMAC (Collaborative Computational Project, Number 4,
1994) with eight TLS groups corresponding to CL,V L,C H1
and VH + peptide for each Fab complex. B values for all
protein domainsandsolvent moleculesarereportedinTable2.
An Rfree test set of 5% of the reﬂections was maintained
throughout reﬁnement. Electron-density maps used for
rebuilding included  A-weighted 2Fo   Fc and Fo   Fc maps.
Hydrogen bonds and van der Waals contacts were evaluated
with HBPLUS (McDonald & Thornton, 1994) and
CONTACSYM (Sheriff et al., 1987). Buried molecular-surface
areas were calculated using the program MS (Connolly, 1993)
with a 1.4 A ˚ probe radius.
3. Results and discussion
3.1. Lattice separation in the epitaxially twinned crystals
Although the crystals grown in the presence of CuCl2
diffracted strongly, they contained two separate lattices of
approximately equivalent intensity with the same unit-cell
parameters, as if two crystals in different orientations had
intergrown (Fig. 1). Multiple crystals were tested, but none
were obtained with a single lattice. Attempts to obtain
strongly diffracting crystals under alternative growth condi-
tions also failed. As a result, data from the epitaxially twinned
crystals were collected and processed with DENZO/SCALE-
PACK (Otwinowski & Minor, 1997) and in-house programs,
as detailed below, to include data from both lattices. While
published descriptions of computer programs for treating
epitaxially twinned data processed with XDS (Lietzke et al.,
1996) and XENGEN (Schulze-Gahmen et al., 1993) are
available, we were unable to ﬁnd any similar programs that
worked with DENZO/SCALEPACK. Since this work was
carried out, a web-based server has been developed in another
laboratory that works with DENZO/SCALEPACK using a
similar scheme to that which we describe here (http://ultr23.-
vub.ac.be/untangle).
Firstly, a standard DENZO/XDISP peak search was used to
ﬁnd spots on the ﬁrst diffraction image. The term ‘spots’ will
be used throughout to deﬁne two-dimensional diffraction
peaks from a single image that result, in most cases, from
partial reﬂections. The spots representing both lattices were
used in the initial DENZO autoindexing. The autoindexing
routine then calculates a unit cell and orientation matrix for
one of the two lattices and using this information ‘spots’ from
‘lattice 1’ only were integrated. An in-house program was then
used to compare the x, y centroid position of each integrated
spot from lattice 1 with the spot positions found by XDISP.
The XDISP spots were then separated into two ﬁles, one
containing the spots within two pixels (1 pixel = 0.1024 mm) of
integrated spots from lattice 1 and a second ﬁle containing the
remaining spots, which predominantly belong to lattice 2
(Fig. 1). Each of these XDISP spot ﬁles was used as input to
the autoindexing routine in DENZO, resulting in a unit cell
and orientation matrix for each lattice. All frames were then
integrated twice, once with each orientation matrix, resulting
in ﬁles containing integrated spots from each of the two
lattices. The two lattices are related by an approximate
twofold rotation around the c axis of the crystal.
To deal with the problem of overlapping spots that arise
from both lattices, another program was written to read in the
ﬁles containing the integrated spots for each lattice on a
frame-by-frame basis and then delete spots whose predicted
centroid positions (in pixel units) are within two pixels (1 pixel
= 0.1024 mm) of each other. The partial spots were then
summed and proﬁle-ﬁtted to create the integrated intensities
(observations) and scaled using SCALEPACK (to obtain
unique reﬂections) for each of the individual lattices and also
for the merged lattices (lattice 1 + 2) with and without over-
lapping-spot deletion. We generated six data sets using these
criteria (see Table 1) in order to evaluate the best method for
treating these data. Two to three rounds of initial model
reﬁnement with CNS were then carried out with each data set
to determine which would yield the best quality model, as
judged by R values and stereochemistry. Structures could be
readily reﬁned with all six data sets (see x2) with electron-
density maps of similar quality. The Rcryst and Rfree values are
also very similar (Table 1). The ﬁnal structure reported here
was determined at 2.1 A ˚ from the sixth data set in Table 1,
which was chosen because it had the lowest Rcryst/Rfree values
of the six data sets. The ﬁnal statistics listed in Table 2 are for
the sixth data set, but with model rebuilding and complete
reﬁnement in addition to the preliminary reﬁnements
reported for the initial tests of the six data sets in Table 1.
3.2. Structure of Fab 447-52D
Fab 447-52D was crystallized with a 23-mer V3 peptide
designated UG1033 (NNTRKSIHLGPGRAFYATGDIIG).
Processing and reﬁnement statistics for the 2.1 A ˚ structure are
reported in Table 2. The crystallographic asymmetric unit
contains two Fab complexes related by a noncrystallographic
(NCS) twofold axis around x (or z). Slightly higher B values
and weaker electron density were observed in the second Fab
complex, indicating a higher degree of ﬂexibility for this
complex. The C
  r.m.s. deviations for the equivalent variable
light-chain (VL) and heavy-chain (VH) regions are 0.31 and
0.22 A ˚ , respectively, and 0.43 A ˚ for the V3 peptide. Because
the two structures are so similar, only the ﬁrst of the two
molecules is discussed here unless noted otherwise. The Fab
chains are numbered according to the Kabat and Wu
convention (Kabat et al., 1987) and the peptide is numbered
according to the HIV-1 HxBc2 numbering convention (Ratner
et al., 1987). The heavy and light chains are designated chains
research papers
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and the peptides are designated chains P and Q for Fabs 1 and
2, respectively. The elbow angles of the two Fabs are 212  and
207 , which are consistent with rather large elbow angles
frequently observed for other Fabs with   light chains (Stan-
ﬁeld, Zemla et al., 2006). Only three residues in the two
complexes fall in the disallowed region of the Ramachandran
plot. Asn
L51 and Asn
M51 are in a highly conserved  -turn that
is found in almost all Fabs (Stanﬁeld et al., 1999) and Asp
M151
is in a loop which also has well ordered density. One residue,
Ser
H134, lies within the generously allowed region of the
Ramachandran plot and is within in a poorly ordered region of
CH1 that tends to be disordered in most
Fabs. Although CuCl2 was part of the crys-
tallization solution, no density was found
that could be assigned to copper or chloride
ions.
An overview of the Fab 447-52D structure
is illustrated in Fig. 2. As expected based on
length and sequence, the light-chain CDR1
and CDR2 belong to canonical classes L1-1
and L2-2 and the heavy-chain CDR1 and
CD2 to classes 1 and 4, respectively. As
reported previously, the light-chain CDR3
of Fab 447-52D contains a three-residue
insertion (L95a–L95c) that makes it longer
than other CDR L3 loops classiﬁed to date
(Stanﬁeld et al., 2004). The 20-residue
heavy-chain CDR3 (H3) forms an extended
structure, approximately 32 A ˚ from base to
tip, which projects outwards from the
molecule. The extended structure is stabi-
lized by a hydrogen-bonding network
between the N- and C-terminal regions of
the CDR H3 loop.
3.3. Structure of the UG1033 V3 peptide
The majority of clade A and C isolates
contain the V3-crown sequence GPGQ.
However, the clade A UG1033 sequence
corresponds to the dominant crown motif,
GPGR, typically found in clade B. Although
the UG1033 peptide is 23 residues in length,
strong interpretable electron density was
only present for ten residues (Fig. 3).
Weaker electron density was present for an
additional three residues (Phe
P317,T y r
P318
and Ala
P319), which are also included in the
ﬁnal model. The remaining C-terminal resi-
dues could not be built into the ﬁnal model
owing to very weak electron density, which
is likely to be a consequence of the confor-
mational ﬂexibility of this region of the
peptide, as frequently observed in other V3-
loop complexes with Fabs (Ghiara et al.,
1994, 1997; Rini et al., 1993; Stanﬁeld et al.,
1993, 1999, 2003, 2004; Stanﬁeld, Gorny et
al., 2006).
The V3 peptide binds alongside the
extended CDR H3 (Fig. 2), forming a three-
stranded mixed  -sheet with CDR H3
(Fig. 4a). The majority of contacts between
research papers
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Figure 2
Stereoview of the Fab 447-52D–UG1033 peptide complex. The Fab is colored gray, with the
light chain oriented to the left and the heavy chain oriented to the right. Complementarity-
determining regions (CDRs) L1, L2 and L3 are colored purple, orange and cyan, respectively.
CDRs H1, H2 and H3 are colored blue, green and red, respectively. The UG1033 V3 peptide is
colored yellow. This and subsequent ﬁgures were generated with PyMOL (DeLano, 2002).
Figure 3
Stereoview of electron density of the UG1033 peptide bound to Fab 447-52D. The 2Fo   Fc
electron density (gray) for the UG1033 V3 peptide (yellow) after reﬁnement is contoured at
1.0 .the Fab and peptide are main-chain hydrogen bonds between
the N-terminal half of the peptide and the C-terminal portion
of the CDR H3 (Fig. 4b), although with fewer regular
hydrogen bonds to the fourth strand. Five main-chain
hydrogen bonds are formed between the following Fab and
V3-peptide residues in the two independent complexes:
Asp
H100f N—Lys
P305 O (3.2/3.1 A ˚ ), Asp
H100f O—Ile
P307 N (2.8/
2.6 A ˚ ), Tyr
H100h N—Ile
P307 O (2.8/2.8 A ˚ ), Tyr
H100h O—
Leu
P309 N (2.8/2.8 A ˚ ), Tyr
H100j N—Leu
P309 O (3.0/3.0 A ˚ ). A
sixth hydrogen bond is made between the side chains of
His
P308 N
 1 and Tyr
H100j OH (2.5/2.6 A ˚ ). The peptide is also
anchored into the Fab-binding site by a salt bridge between
the side chains of Arg
P315 NH1 and Asp
H95 O
 2 (2.5/2.5 A ˚ ;
Fig. 4c) and Arg
P315 also forms  –cation interactions with
Trp
H33 and Tyr
H100j. The guanidinium moiety of Arg
P315 is
sandwiched between the indole ring of Trp
H33 and the phenyl
ring of Tyr
H100j, with distances of approximately 3.7 and 3.5 A ˚
from the N
" atom of Arg
P315 to the center of the tyrosine and
tryptophan rings, respectively. Pro
P313 is cradled between the
indoles of Trp
L91 and Trp
L96 in the antibody-combining site
(Fig. 4c). The conserved V3-crown motif, GPGR, forms a type
II  -turn (’i+1 =  71 ,  i+1 = 138  for Pro
P313, ’i+2 =7 8  ,
 i+2 =2   for Gly
P314), as previously observed in the Fab 447-
52D in complex with an MN V3 peptide (Stanﬁeld et al., 2004).
110 and 141 van der Waals interactions are made in the two
Fab–peptide complexes, respectively. The buried molecular-
surface areas of the Fab and peptide are 553/587 and 522/
487 A ˚ 2 for the two Fab–peptide complexes. The buried surface
area of the Fab is largely formed by aromatic tyrosine and
tryptophan residues (69%/65%), followed by acidic (19%/
20%), basic (6.4%/6.2%), polar (2.4%/4.1%) and small and/or
hydrophobic residues (3.3%/4.9%).
3.4. Comparison with the Fab 447-52D–MN V3-peptide
complex
Only minor differences are observed between the structure
of the Fab 447-52D complex reported above and the Fab 447-
52D–MN V3 peptide complex previously reported by our
group (Stanﬁeld et al., 2004) based on comparisons calculated
using the ﬁrst molecule of the asymmetric unit of each crystal
structure. When the most highly ordered residues in the
peptides are superimposed (Lys
P305–Ala
P316), the r.m.s.
deviation (r.m.s.d.) of the C
  backbone for the different V3
peptides is 0.45 A ˚ , with the largest deviation (1.0 A ˚ ) being at
Ala
P316 (Fig. 5). The UG1033 V3-peptide structure extends an
additional three residues beyond Ala
P316, although the density
research papers
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Table 3
Backbone torsion angles for the UG1033 peptide structures complexed
with Fab 447-52D and Fab 2219 and the equivalent V3 loop from a gp120
structure.
’ ( ), UG1033 V3 in   ( ), UG1033 V3 in
Residue
Fab
447-52D
Fab
2219†
gp120
V3‡
Fab
447-52D
Fab
2219†
gp120
V3‡
305 n/a  78  124 135  30  12
306  140  70  147 125 138 146
307  103  109  118 138 120 160
308  125  85  129 114 106 121
309  113  73  84 94  39 140
312  170  165  158 171  175 131
313  71  60  59 138 126 99
314 78 71 100 2 12 8
315  91  139  172 134 144 149
316  69  158  13 190 154 167
317  21  109  133  61 157 153
318  87 54 60 158 38 65
319  156  88  150 n/a 170  2
† Torsion angles were calculated from the structure with PDB code 2b1a. ‡ Torsion
angles are those reported by Stanﬁeld, Gorny et al. (2006) from analysis of the structure
with PDB code 2b4c (Huang et al., 2005).
Figure 4
Binding-site interactions between the UG1033 V3 peptide and Fab 447-52D. The Fab CDR H3 is shown in violet and the UG1033 peptide in yellow. (a)
The mixed three-strand  -sheet formed by CDR H3 and the V3 peptide is shown. (b) The main-chain hydrogen-bond interactions in the three-strand
 -sheet are represented by black dotted lines. (c) Side-chain interactions between the UG1033 peptide and the Fab light chain (cyan) and heavy chain
(violet).for the extra three residues is weak. In the UG1033 V3-
peptide structure, Tyr
P318 contacts a symmetry-related Lys
L156
in the second molecule in the asymmetric unit, but not in the
ﬁrst molecule. This contact is not made in the MN V3-peptide
complex owing to a slight difference in the packing of the
molecules. It is not clear whether this contact has helped to
stabilize these residues or whether the stronger peptide
density is a function of the better diffraction of the UG1033
V3-peptide complex crystals. The GPGR crown motif also
adopts a type II  -turn in each of the two structures. The two
different Fab 447-52D structures also do not differ signiﬁ-
cantly, with C
  backbone r.m.s.d. values of 0.24 A ˚ for the VL
domain and 0.34 A ˚ for the VH domain. Notably, inclusion of
an additional three residues in the C-terminal portion of the
UG1033 peptide also does not increase the peptide-binding
interactions with Fab 447-52D.
The UG1033 V3-peptide sequence differs from the MN
peptide at two positions. An arginine is present at position
P306 and an isoleucine at position P309 in the MN peptide,
whereas serine and leucine are found in these positions,
respectively, in the UG1033 peptide. However, as expected,
these differences in sequence do not affect the main-chain
hydrogen bonds that the peptide forms with Fab 447-52D
CDR H3. Although P317–P319 at the C-terminus of the
UG1033 peptide do not interact with the Fab, they contact the
N-terminal strand of the V3 peptide through main-chain
hydrogen bonds to form a more regular  -hairpin-type struc-
ture. An evaluation of hydrogen-bond contacts detects addi-
tional hydrogen bonds in each peptide between Phe
P317 O and
His
P308 N (2.8/2.6 A ˚ ) and a second hydrogen bond in the
second peptide between Ala
Q319 N and Ser
Q306 O (2.7 A ˚ ). The
distance between Ala
P319 N and Ser
P306 O increases slightly in
the ﬁrst peptide to 3.1 A ˚ , although the density at the
C-terminus is weaker.
3.5. Comparison with Fab 2219–UG1033 and gp120 V3 core
structures
The UG1033 peptide structure has also been determined in
complex with the V3-speciﬁc Fab 2219 (Stanﬁeld, Gorny et al.,
2006). As observed here, the GPGR motif also forms a type II
 -turn in the Fab 2219 structure, with a C
  r.m.s.d. of 0.21 A ˚ to
the Fab 447-52D structure (Gly
P312–Arg
P315). However, a
difference in one of the dihedral angles ( ) of Leu
P309 results
in a change in the orientation of the peptide backbone
(Table 3). Hence, the carbonyl O atoms of the N-terminal
residues preceding Leu
P309 are rotated by about 180  in the
Fab 2219 complex with respect to the conformation seen in the
Fab 447-52D complex (Fig. 6). Despite this difference, the N-
and C-terminal strands of the hairpin independently show
close structural homology with the UG1033 peptide in the Fab
447-52D structure, with C
  backbone r.m.s.d. values of 0.60 A ˚
(Lys
P305—Gly
P312) and 0.86 A ˚ (Ala
P316—Ala
P319).
When bound to Fab 2219, the majority of contacts are made
through side chains of residues in the N-terminal strand of the
UG1033 peptide, although two side-chain contacts from
C-terminal residues are also observed. Despite making contact
with the Fab 2219, N-terminal residues Thr
P303–Ser
P306 are still
solvent-exposed. It is likely that Fab 2219 is able to tolerate
diversity in side chains at these positions because of the
solvent-accessible nature of these residues. In contrast, the use
of main-chain hydrogen-bond contacts allows Fab 447-52D to
tolerate diversity within the N-terminal region of the V3. In
both structures, Arg
P315 makes side-chain contacts with the
Fab and forms salt bridges to Asn
L31 in Fab 2219 and to Asp
H95
in Fab 447-52D. However, the UG1033 V3 crown is also
largely accessible in the Fab 2219 complex, whereas it is less
accessible and oriented into the antibody-binding pocket in
the Fab 447-52D complex reported here.
The structure of the UG1033 V3 peptide in the Fab 447-52D
complex also reveals structural homology to the V3 region of
gp120-containing V3 crystal structures (Fig. 6). The C
  back-
bone r.m.s.d. values of the UG1033 peptide with the corre-
sponding V3 loop in the reported gp120 V3 structure (Huang
et al., 2005) are 0.56 and 0.85 A ˚ for the N-terminal (Lys
P305–
Gly
P312) and C-terminal (Ala
P316–Ala
P319) strands respec-
tively, and 0.59 A ˚ for the GPGR crown motif. A gp120-
containing V3 structure in complex with a tyrosine-sulfated
antibody has recently been reported (Huang et al., 2007). The
GPGR crown of the V3 loop in this structure exhibits even
greater structural homology with the crown of the UG1033 V3
peptide, with a C
  backbone r.m.s.d. value of only 0.16 A ˚ .
3.6. Comparison with NMR structures
The structures of MN and IIIB V3 peptides in complex with
447-52D Fv have also been determined by NMR methods.
Solution (Sharon et al., 2003) and solid-state (Sharpe et al.,
2004) NMR studies of MN V3 peptides (residues 303–325 and
305–322 of the MN V3 loop,respectively) in complex with 447-
research papers
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Figure 5
Comparison of the UG1033 and MN peptides bound to Fab 447-52D. A
superposition of the C
  backbones of the UG1033 V3 peptide bound to
Fab 447-52D and the MN V3-peptide structure previously solved in
complex with Fab 447-52D is shown. The UG1033 peptide is shown in
yellow and the MN peptide in blue. The UG1033-peptide residues are
labeled.52D Fv show an overall similarity to the structure reported
here (Fig. 7). In the NMR studies, the MN peptide forms a
 -hairpin stabilized by intrapeptide hydrogen-bond inter-
actions (Gly
312 O—Gly
314 N, Arg
315 O—Thr
319 N, Thr
319 O—
Arg
315 N, His
308 O—Phe
317 N and Phe
317 O—His
308 N) with
an inverse  -turn at the crown. The extended C-terminal
portion of the  -hairpin is not observed here, which is likely to
be the consequence of ﬂexibility of the C-terminal residues in
the UG1033 peptide. However, the overall shape of the
peptides is similar (Fig. 7), with a C
  r.m.s.d. of 1.7 A ˚ for
Lys
P305–Ala
P319. In the MN–447-52D Fv solution NMR
structure, strong interactions between the Fv and peptide are
reported for N-terminal peptide residues Lys
P305–Arg
P315 and
weaker interactions are reported for the C-terminal Ala
P316–
Thr
P320. Although the same C-terminal
interactions are not observed here, the
N-terminal residues of the UG1033
peptide still dominate binding to Fab
447-52D. Moreover, in the solid-state
NMR structure of the MN V3–447-52D
Fv complex, the C-terminal interactions
could not be observed. The side chains
of Gly
P312, Pro
P313 and Arg
P315 are also
reported to interact with aromatic rings
of the Fv in the NMR structures, which
is in agreement with our observation
that Pro
P313 is ﬂanked by the indoles of
Trp
L91 and Trp
L96 and that Arg
P315
makes  –cation interactions with
Tyr
H100j and Trp
H33.
The NMR structure of a IIIB V3
peptide (residues 303–322) in complex
with 447-52D Fv has also been reported
(Rosen et al., 2005). The V3 loop of
HIV-1IIIB contains a two-residue inser-
tion (QR) before the GPGR crown
sequence. In the IIIB V3–Fv structure the peptide forms a
 -hairpin, although the QR insertion creates a kink before the
 -turn at the crown. Despite the two-residue insertion, the
resulting structure is very similar to the UG1033 crystal
structure and the MN NMR structure (Fig. 7) discussed above,
with the N-terminal residues dominating binding to 447-52D.
The similarity of the overall peptide conformation is evident
when the UG1033 N-terminal strand (Lys
P305–Leu
P309),  -turn
(Gly
P312–Arg
P315) and C-terminal strand (Ala
P316–Ala
P319) are
superimposed with the corresponding IIIB peptide residues,
giving C
  backbone r.m.s.d. values of 0.64, 0.30 and 1.82 A ˚ ,
respectively. Based on a 2D-homonuclear TOSCY spectrum,
Rosen and coworkers also conclude that IIIB residues Ile
P309
and Gly
P312 are likely to interact with aromatic tyrosine side
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Figure 7
Comparison of the crystal structure of the UG1033 peptide bound to Fab 447-52D with the NMR
structures of the MN and IIIB peptides bound to 447-52D Fv. The C
 -backbone structures are
shown in a similar orientation for (a) the UG1033 V3 peptide from the crystal structure and (b)M N
(PDB code 1n1z) and (c) IIIB (PDB code 1u6u) from NMR structures. The N-terminus of each
peptide is oriented to the left.
Figure 6
Comparison of V3 crystal structures. The C
 -backbone structures are shown in a similar orientations for (a) the UG1033 V3 peptide bound to Fab 447-
52D (b) the UG1033 V3 peptide bound to Fab 2219 (PDB code 2b1a) and the V3 loops from two gp120 core complexes: (c) PDB code 2b4c and (d) PDB
code 2qad. Two conformations were observed for the V3 crown in the core gp120 V3 structure with PDB code 2b4c and both of these conformations are
shown in (c).chains of the Fv and Pro
P313 and Gly
P314 are likely to interact
with tryptophan residues. In the UG1033 structure, Leu
P309 is
positioned near Tyr
H100i and Tyr
L32, and Gly
P312, Pro
P313 and
Gly
P314 are close to Trp
L91,T r p
L96 and Trp
H33. These aromatic
contacts are not identical to those proposed in the IIIB–
447-52D Fv NMR structure. However, as previously suggested
(Rosen et al., 2005), the QR insertion in the IIIB peptide may
alter the positioning of the peptide in the 447-52D binding site.
4. Conclusions
The structure of the UG1033 peptide in complex with Fab 447-
52D has been determined from an epitaxially twinned data set
where the individual lattices were separated and overlapping
reﬂections were removed. The ﬁnal Rcryst and Rfree values of
the model are higher than expected at this resolution, which is
likely to be the consequence of some residual overlapping
spots (diffraction maxima) that were not removed by the
procedure. However, given the quality and resolution of the
electron-density maps, the Fab–peptide complex can still be
determined with conﬁdence. Moreover, this structure shows
very high structural homology to the crystal structure of the
MN V3 peptide in complex with Fab 447-52D previously
reported by our group (Ghiara et al., 1994, 1997; Rini et al.,
1993; Stanﬁeld et al., 1993, 1999, 2003, 2004; Stanﬁeld &
Wilson, 2005) and to the NMR structure (Sharon et al., 2003),
further validating the ﬁnal model built from the epitaxially
twinned data set.
The structure of the Fab 447-52D complex reported here
conﬁrms our previous conclusion that the breadth of this
neutralizing antibody is attributable to the use of main-chain
hydrogen bonds to contact the N-terminal region of the V3-
loop backbone (Stanﬁeld et al., 2004). This mode of antigen
recognition enables 447-52D to bind a diverse range of V3
sequences. We observe here that a two-residue sequence
difference between the UG1033 peptide and the MN peptide
previously determined in complex with Fab 447-52D (Arg
P306–
Ser
P306 and Ile
P309–Leu
P309) does not alter the binding inter-
actions between the V3 peptides and Fab. The reported
dependence of antigen recognition on the presence of the
conserved crown motif GPxR (Keller et al., 1993) can be
explained in part by the observation that the crown and in
particular Arg
P315 form speciﬁc interactions with the antibody-
binding site. Finally, the V3-peptide structure shows a high
level of structural homology with previously reported V3
crystal and NMR structures, supporting the hypothesis that
the V3 loop of gp120 may adopt a conserved structure or
limited set of structures, particularly at the crown (Zolla-
Pazner, 2004; Ghiara et al., 1994, 1997; Rini et al., 1993;
Stanﬁeld et al., 1993, 1999, 2003, 2004; Stanﬁeld, Gorny et al.,
2006; Stanﬁeld & Wilson, 2005; Cardozo et al., 2007; Rosen et
al., 2006). Future structural studies of such V3-speciﬁc
neutralizing antibodies in complex with a diverse range of V3
peptides will help to further clarify conserved structural
features of the V3 loop, as well as the precise mechanism by
which V3 antibodies recognize their epitopes. This informa-
tion will in turn provide valuable insight into how the V3
region of gp120 may be utilized as an anti-HIV-1 immunogen
that may provide some efﬁcacy in combination with immu-
nogens corresponding to other epitopes.
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